futibatinib sold brand name lytgobi anticancer medication used treatment cholangiocarcinoma bile duct kinase taken futibatinib approved medical use united states september japan june european union july futibatinib indicated treatment adults previously treated unresectable locally advanced metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor gene fusions april committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting conditional marketing authorization medicinal product lytgobi intended secondline treatment locally advanced metastatic cholangiocarcinoma characterized fusion rearrangements fibroblast growth factor receptor fgfr applicant medicinal product taiho pharma netherlands futibatinib approved medical use european union july futibatinib international nonproprietary name pharmacologyrelated article stub help wikipedia expanding httpsenwikipediaorgwikifutibatinib